A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Exclusion Criteria

• •1. Subjects with central nervous system involvement, etc.;
• •2. Use of chemotherapy, biologics, immunotherapy, etc., within 4 weeks prior to the first dose or within 5 half-lives;
• •3. History of severe heart disease;
• •4. QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block;
• •5. Active autoimmune diseases and inflammatory diseases;
• •6. Diagnosis of other malignancies within 5 years prior to the first dose;
• •7. Hypertension poorly controlled by two antihypertensive medications;
• •8. Patients with poorly controlled blood glucose;
• •9. Unstable thrombotic events requiring therapeutic intervention within 6 months prior to the first dose;
• •10. Lung diseases defined as ≥ Grade 3 according to CTCAE v5.0; history of interstitial lung disease requiring hormone treatment, etc.;
• •11. Patients with peripheral neuropathy ≥ Grade 3 or persistent ≥ Grade 2 peripheral neuropathy with pain;
• •12. Patients with a history of allergy to recombinant humanized antibodies or human-mouse chimeric antibodies, or allergy to any excipient component of BL-M24D1;
• •13. Previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT);
• •14. Human immunodeficiency virus antibody positivity, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
• •15. Active infection requiring systemic treatment within 4 weeks prior to the first study drug administration, etc.;
• •16. Pleural, abdominal, pelvic, or pericardial effusion requiring drainage and/or accompanied by symptoms within 4 weeks prior to the first study drug administration;
• •17. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to the first study drug administration;
• •18. Participation in another clinical trial within 4 weeks prior to the first dose;
• •19. Pregnant or breastfeeding women;
• •20. Patients who received live vaccines within 30 days prior to the first dose;
• •21. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.